Study details
Enrolling now
Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling
National Heart, Lung, and Blood Institute (NHLBI)
NCT IDNCT06313398ClinicalTrials.gov data as of Apr 2026
Phase
EARLY_PHASE1
Target enrollment
100
Study length
about 5.1 years
Ages
18–100
Locations
1 site in MD
About this study
This trial is testing how long red blood cells survive in people with sickle cell disease (SCD) and other hemoglobinopathies. The researchers will use biotin labeling to track the lifespan of these cells, comparing them to those who have had a bone marrow transplant. This information could help improve treatments for these conditions.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Biotin-labeled red blood cells
PhaseEARLY_Phase 1
DrugBiotin-labeled red blood cells
Routeoral
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low9%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
ALIMENTARY TRACT AND METABOLISM
Drug routes
oral (Oral Tablet)